AnaptysBio (Rights to Imsidolimab) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

AnaptysBio (Rights to Imsidolimab) General Information

Description

Drug rights for rare skin disorder.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • San Diego, CA
  • United States
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Corporate Office
  • San Diego, CA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AnaptysBio (Rights to Imsidolimab) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AnaptysBio (Rights to Imsidolimab)‘s full profile, request access.

Request a free trial

AnaptysBio (Rights to Imsidolimab) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AnaptysBio (Rights to Imsidolimab)‘s full profile, request access.

Request a free trial

AnaptysBio (Rights to Imsidolimab) FAQs

  • Where is AnaptysBio (Rights to Imsidolimab) headquartered?

    AnaptysBio (Rights to Imsidolimab) is headquartered in San Diego, CA.

  • What industry is AnaptysBio (Rights to Imsidolimab) in?

    AnaptysBio (Rights to Imsidolimab)’s primary industry is Buildings and Property.

  • Is AnaptysBio (Rights to Imsidolimab) a private or public company?

    AnaptysBio (Rights to Imsidolimab) is a Private company.

  • What is AnaptysBio (Rights to Imsidolimab)’s current revenue?

    The current revenue for AnaptysBio (Rights to Imsidolimab) is .

  • Who are AnaptysBio (Rights to Imsidolimab)’s investors?

    AnaptysBio has invested in AnaptysBio (Rights to Imsidolimab).

  • When was AnaptysBio (Rights to Imsidolimab) acquired?

    AnaptysBio (Rights to Imsidolimab) was acquired on 26-Feb-2026.

  • Who acquired AnaptysBio (Rights to Imsidolimab)?

    AnaptysBio (Rights to Imsidolimab) was acquired by Vanda Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process